Medicinal Chemistry Journal of Medicinal Chemistry
Tricyclic pteridinone yields an oral HPK1 inhibitor that pairs with anti-PD-1
- Structure-guided scaffold hopping and ring optimization from a known diaminopyrimidine carboxamide HPK1 chemotype gave a new tricyclic pyrido[2,1-h]pteridin-6-one core.
- Lead 29 is highly potent with strong kinase selectivity, blocks SLP-76 phosphorylation and boosts T-cell activation in Jurkat cells and human PBMCs.
- It shows good oral exposure and, combined with anti-PD-1 in the CT26.WT syngeneic model, clearly improves tumor control.
Tricyclisation plausibly pre-organises the hinge-binding conformation and cuts the entropic cost, so the design logic is easy to follow. The harder test is selectivity within the MAP4K family, notably GLK, and against T-cell kinases such as LCK, where off-target activity could undercut the immune benefit. The combination result also lacks a monotherapy arm and an inactive analogue to show it is on-target.
Paper: Journal of Medicinal Chemistry ↗ Discovery of a Novel Pyrido[2,1-h]pteridin-6-one Derivative as a Potent and Orally Bioavailable HPK1 Inhibitor